RE:RE:RE:UOB KayHian on Genting/TaurxAgree on lazy TauRx valuation using a 2017 wall street journal article re: possible IPO.
My guess is TauRx will partner to distribute HMTM in the US. Any announcement on this partnership perhaps prior to FDA approval may offer some insight on valuation. Especially if this partnership is concurent with an equity financing.